Aemetis (AMTX) Stock Forecast & Price Target

Aemetis is viewed positively because its fiscal Q2 2026 revenue rose to $63 million from $52 million year over year, while EPS of $(0.16) outperformed both estimates and consensus, signaling improving operating leverage despite ongoing losses. The company’s Q2 gross margins, operating income, and EBITDA were described as very positive, and its biogas platform is gaining scale with expansion to 15 dairies, 40 miles of pipeline installed, and over 50 dairy agreements signed. Supportive catalysts include potential year-round E15 approval, CARB pathway approval for dairy digester RNG, Section 45Z credits extended to 2029, and a likely rebound in the India business with new contracts in 2026 and an IPO soon.

Aemetis is facing a weak fundamental setup as losses remain elevated, with a net loss of $22 million versus an expected $15 million loss, while estimates were cut for 2026 revenue to $270 million from $285 million and EPS to $(1.12) from $(0.86). The company’s balance sheet remains highly leveraged, with about $5 million in cash against $533 million in debt, leaving little financial flexibility and heightening liquidity risk. Its repeated multi-year revenue goals have also been pushed back—from $1 billion in revenue in 2025 to $1 billion in 2026 and $2 billion in 2028—while regulatory, commodity, and alternative-energy incentive risks continue to cloud execution.